Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years

H7N9 Influenza Clinical Trial

Official title:
Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years

Status Completed

Clinical Trial Summary

Evaluate the safety and immunogenicity of four different doses of H7N9 vaccination in adults between the ages of 18 years and 65 years.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01928472
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 1
Start date	August 2013
Completion date	September 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03330899` - Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil	Phase 1
Not yet recruiting	`NCT03755427` - A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine	Phase 2
Not yet recruiting	`NCT06417853` - Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP)	Phase 1
Active, not recruiting	`NCT03369808` - A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine	Phase 1/Phase 2